Mind Medicine (MindMed) Inc
MNMD12.100USD
-0.190-1.55%
Handelsschluss 11/03, 16:00（ET）Kurse um 15 Minuten verzögert
917.22MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Mind Medicine (MindMed) Inc Unternehmen
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Mind Medicine (MindMed) Inc Informationen
BörsenkürzelMNMD
Name des UnternehmensMind Medicine (MindMed) Inc
IPO-datumMay 04, 2015
CEOMr. Robert (Rob) Barrow
Anzahl der mitarbeiter74
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
AddresseOne World Trade Center
StadtNEW YORK
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl10007
Telefon12122206633
Websitehttps://ir.mindmed.co/
BörsenkürzelMNMD
IPO-datumMay 04, 2015
CEOMr. Robert (Rob) Barrow
Führungskräfte von Mind Medicine (MindMed) Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Andere
79.04%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Andere
79.04%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
22.81%
Hedge Fund
16.77%
Investment Advisor
13.84%
Research Firm
1.64%
Individual Investor
1.03%
Bank and Trust
0.36%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Andere
43.15%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
383
42.48M
55.83%
-5.92M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
5.22M
6.86%
+17.02K
+0.33%
Jun 30, 2025
Commodore Capital LP
5.00M
6.57%
+475.00K
+10.50%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.71%
--
--
Jun 30, 2025
Marshall Wace LLP
3.42M
4.5%
+828.07K
+31.93%
Jun 30, 2025
Driehaus Capital Management, LLC
3.09M
4.06%
-258.75K
-7.72%
Jun 30, 2025
Deep Track Capital LP
2.50M
3.29%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
2.13M
2.8%
-888.00K
-29.42%
Jun 30, 2025
State Street Investment Management (US)
1.81M
2.37%
-36.32K
-1.97%
Jun 30, 2025
The Vanguard Group, Inc.
1.80M
2.37%
+47.45K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.73M
2.28%
+66.66K
+4.00%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
AdvisorShares Psychedelics ETF
10.44%
SPDR S&P Pharmaceuticals ETF
1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.17%
iShares U.S. Pharmaceuticals ETF
0.33%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
Vanguard US Momentum Factor ETF
0.07%
Nuveen ESG Small-Cap ETF
0.06%
Mehr Anzeigen
AdvisorShares Psychedelics ETF
Anteil10.44%
SPDR S&P Pharmaceuticals ETF
Anteil1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.17%
iShares U.S. Pharmaceuticals ETF
Anteil0.33%
iShares Micro-Cap ETF
Anteil0.19%
ProShares Ultra Nasdaq Biotechnology
Anteil0.09%
Invesco Nasdaq Biotechnology ETF
Anteil0.09%
Vanguard US Momentum Factor ETF
Anteil0.07%
Nuveen ESG Small-Cap ETF
Anteil0.06%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Datum
Art
Verhältnis
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
